DC
EPZM

Diametric Capital’s Epizyme, Inc EPZM Stock Holding History

Diametric Capital’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-30,920
Closed -$497K – 206
2020
Q2 		$497K Buy
30,920
+584
+2% +$10.2K 0.38% 76
2020
Q1 		$471K Buy
30,336
+6,332
+26% +$136K 0.57% 59
2019
Q4 		$590K Buy
+24,004
New +$356K 0.43% 77
2019
Q3 		– Sell
-156,575
Closed -$1.97M – 151
2019
Q2 		$1.97M Buy
+156,575
New +$2.01M 1.25% 28

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Diametric Capital's EPZM Position: Q3 2020 in Review

Diametric Capital sold out of Epizyme, Inc (EPZM) in Q3 2020, closing a stake of 30,920 shares — an estimated $497K sold.

Diametric Capital first reported a position in EPZM in Q2 2019 and held it in 4 quarters. The position peaked at $1.97M in Q2 2019. 151 funds tracked by Wall St. Rank hold EPZM as of Q3 2020.

  • Diametric Capital reported no remaining Epizyme, Inc position as of Q3 2020 after selling out during the quarter.
  • Diametric Capital sold 30,920 Epizyme, Inc shares in Q3 2020, an estimated $497K.
  • Diametric Capital first reported a position in Epizyme, Inc in Q2 2019 and held it in 4 quarters.
  • Diametric Capital's Epizyme, Inc position peaked at $1.97M in Q2 2019.
  • 151 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2020.

Based on Diametric Capital's 13F filing for Q3 2020, filed 13 Nov 2020.